Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: Comparison with cariprazine

CNS Spectrums

Volumn 22, Issue 6, 2017, Pages 484-494

  Choi, Yong Kee ^a   Adham, Nika ^b   Kiss, Béla ^c   Gyertyán, István ^d,e   Tarazi, Frank I ^a  

^a MCLEAN HOSPITAL   (United States)

^b Allergan ^*  (United States)

^c GEDEON RICHTER LTD   (Hungary)

^d SEMMELWEIS UNIVERSITY   (Hungary)

^e Research Centre for Natural Sciences Hungarian Academy of Sciences   (Hungary)

Author keywords

Aripiprazole; autoradiography; bipolar mania; cariprazine; dopamine; glutamate; schizophrenia; serotonin

Indexed keywords

AMPA RECEPTOR; ARIPIPRAZOLE; CARIPRAZINE; GLUTAMATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; CAUDATE PUTAMEN LATERAL; CAUDATE PUTAMEN MEDIAL; CONTROLLED STUDY; DORSAL STRIATUM; DORSOLATERAL FRONTAL CORTEX; DRUG EFFECT; DRUG EXPOSURE; ENTORHINAL CORTEX; FRONTAL CORTEX; GLUTAMATERGIC SYNAPSE; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA3 REGION; LONG TERM EXPOSURE; MALE; MEDIAL PREFRONTAL CORTEX; MONOAMINERGIC NERVE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; ANIMAL; COMPARATIVE STUDY; FOREBRAIN; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; MALE; PIPERAZINES; PROSENCEPHALON; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, AMPA; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, N-METHYL-D-ASPARTATE; TIME;

EID: 85008386003     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852916000894     Document Type: Article

References (56)

1. Baldessarini RJ, Tarazi FI. Pharmacotherapy of psychosis and mania. In: Brunton LL, Lazo JS, Parker K, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 2005: 461-500.
2. Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 2012; 37(1): 4-15; Epub ahead of print Sep 28, 2011. https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC3238069/pdf/npp2011181a.pdf.
3. Eggers AE. A serotonin hypothesis of schizophrenia. Med Hypotheses. 2013; 80(6): 791-794; Epub ahead of print Apr 1.
4. Hu W, MacDonald ML, Elswick DE, Sweet RA. The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies. Ann N Y Acad Sci. 2015; 1338: 38-57; Epub ahead of print Oct 14, 2014. https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC4363164/pdf/nihms625030.pdf.
5. Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol. 2011; 11(1): 59-67; Epub ahead of print Mar 21.
6. Ellenbroek BA, Cesura AM. Antipsychotics and the dopamine-serotonin connection. In: Celanire S, Poli S, eds. Small Molecule Therapeutics for Schizophrenia. Cham: Springer International Publishing; 2015: 1-49.
7. Kiss B, Horváth A, Némethy Z, et al. Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010; 333(1): 328-340; Epub ahead of print Jan 21. http://jpet.aspetjournals.org/ content/jpet/333/1/328.full.pdf.
8. Gyertyán I, Kiss B, Sághy K, et al. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int. 2011; 59(6): 925-935.
9. Slifstein M, Abi-Dargham A, D'Souza DC, et al. Cariprazine demonstrates high dopamine D3 and D2 receptor occupancy in patients with schizophrenia: a clinical PET study with [11C]-( + )-PHNO. Neuropsychopharmacology. 2013; 38(Suppl 2): S520.
10. Neill JC, Grayson B, Kiss B, Gyertyan I, Ferguson P, Adham N. Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. Eur Neuropsychopharmacol. 2016; 26(1): 3-14; Epub ahead of print Nov 19, 2015.
11. Papp M, Gruca P, Lason-Tyburkiewicz M, Adham N, Kiss B, Gyertyán I. Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression. Behav Pharmacol. 2014; 25(5-6): 567-574.
12. Zimnisky R, Chang G, Gyertyan I, Kiss B, Adham N, Schmauss C. Cariprazine, a dopamine D3-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology. 2013; 226(1): 91-100; Epub ahead of print Oct 19, 2012. https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC3572273/pdf/nihms416352.pdf.
13. Duman RS, Duric V, Banasr M, Adham N, Kiss B, Gyertyán I. Cariprazine exhibits dopamine D3-receptor-dependent antidepressantlike activity in the chronic unpredictable stress model of anhedonia. Neuropsychopharmacology. 2012; 38(Suppl 1): S84-S85.
14. Tarazi FI, Kiss B, Choi YK, Adham N, Gyertyán I. Effects of chronic aripiprazole administration on dopamine receptors: comparison with cariprazine. Neuropsychopharmacology. 2014; 39: S138-S139.
15. Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology. 2002; 161(3): 263-270; Epub ahead of print Apr 4.
16. Tarazi FI, Moran-Gates T,Wong EH, Henry B, Shahid M. Asenapine induces differential regional effects on serotonin receptor subtypes. J Psychopharmacol. 2010; 24(3): 341-348; Epub ahead of print Aug 21, 2008.
17. Tarazi FI, Florijn WJ, Creese I. Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology. 1996; 128(4): 371-379.
18. Tarazi FI, Baldessarini RJ, Kula NS, Zhang K. Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment. J PharmacolExpTher. 2003; 306(3): 1145-1151; Epub ahead of print Jun 26. http://jpet.aspetjournals.org/content/jpet/306/3/1145.full. pdf.
19. Tarazi FI, Choi YK, Gardner M, Wong EH, Henry B, Shahid M. Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain. Synapse. 2009; 63(5): 413-420.
20. Gao J, Qin R, Li M. Repeated administration of aripiprazole produces a sensitization effect in the suppression of avoidance responding and phencyclidine-induced hyperlocomotion and increases D2 receptor-mediated behavioral function. J Psychopharmacol. 2015; 29(4): 390-400; Epub ahead of print Jan 13. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4757439/ pdf/nihms758943.pdf.
21. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates, 2nd ed. New York: Academic Press; 1986.
22. Florijn WJ, Tarazi FI, Creese I. Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs. J Pharmacol Exp Ther. 1997; 280(2): 561-569 http://jpet.aspetjournals.org/content/jpet/280/2/561.full.pdf.
23. Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Ther. 2001; 297(2): 711-717 http://jpet.aspetjournals.org/content/jpet/297/2/711.full.pdf.
24. Tarazi FI, Yeghiayan SK, Baldessarini RJ, Kula NS, Neumeyer JL. Long-term effects of S( + )N-n-propylnorapomorphine compared with typical and atypical antipsychotics: differential increases of cerebrocortical D2-like and striatolimbic D4-like dopamine receptors. Neuropsychopharmacology. 1997; 17(3): 186-196 http://www.nature.com/npp/journal/v17/n3/full/1395027a.html.
25. Greene WH. Econometric Analysis. Upper Saddle River, NJ: Prentice Hall; 2000. http://stat.smmu.edu.cn/DOWNLOAD/ebook/ econometric.pdf.
26. Winer BJ, Brown DR, Michels KM. Statistical Principles in Experimental Design, 3rd ed. New York: McGraw-Hill; 1991.
27. Choi YK, Adham N, Kiss B, Gyertyán I, Tarazi FI. Long-term effects of cariprazine exposure on dopamine receptor subtypes. CNS Spectr. 2014; 19(3): 268-277; Epub ahead of print Nov 8, 2013.
28. Lammers CH, Diaz J, Schwartz JC, Sokoloff P. Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol Psychiatry. 2000; 5(4): 378-388.
29. Newman-Tancredi A, Assie MB, Leduc N, Ormiere AM, Danty N, Cosi C. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol. 2005; 8(3): 341-356; Epub ahead of print Feb 11.
30. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003; 28(8): 1400-1411; Epub ahead of print May 21.
31. Pazos A, Palacios JM. Quantitative autoradiographic mapping of serotonin receptors in the rat brain, I: serotonin-1 receptors. Brain Res. 1985; 346(2): 205-230.
32. Pompeiano M, Palacios JM, Mengod G. Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding. J Neurosci. 1992; 12(2): 440-453 http://www.jneurosci.org/content/jneuro/12/2/440.full.pdf.
33. Francis PT, Pangalos MN, Pearson RC, Middlemiss DN, Stratmann GC, Bowen DM. 5-Hydroxytryptamine1A but not 5-hydroxytryptamine2 receptors are enriched on neocortical pyramidal neurones destroyed by intrastriatal volkensin. J Pharmacol Exp Ther. 1992; 261(3): 1273-1281.
34. Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn SH. 5-HT1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry. 2000; 48(3): 229-237.
35. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY. 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem. 2001; 76(5): 1521-1531.
36. Bantick RA, Deakin JF, Grasby PM. The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol. 2001; 15(1): 37-46.
37. Christoffersen CL, Meltzer LT. Reversal of haloperidol-induced extrapyramidal side effects in Cebus monkeys by 8-hydroxy-2-(di-n-propylamino)tetralin and its enantiomers. Neuropsychopharmacology. 1998; 18(5): 399-402 http://www. nature.com/npp/journal/v18/n5/full/1395157a.html.
38. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology. 1999; 20(5): 491-505 http://www. nature.com/npp/journal/v20/n5/full/1395273a.html.
39. Millan MJ. Improving the treatment of schizophrenia: focus on serotonin 5-HT1A receptors. J Pharmacol Exp Ther. 2000; 295(3): 853-861 http://jpet.aspetjournals.org/content/jpet/295/3/853. full.pdf.
40. Celada P, Bortolozzi A, Artigas F. Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs. 2013; 27(9): 703-716.
41. Heckers S, Konradi C. GABAergic mechanisms of hippocampal hyperactivity in schizophrenia. Schizophr Res. 2015; 167(1-3): 4-11; Epub ahead of print Oct 18, 2014. https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC4402105/pdf/nihms639551.pdf.
42. O'Dell SJ, La Hoste GJ, Widmark CB, Shapiro RM, Potkin SG, Marshall JF. Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain. Synapse. 1990; 6(2): 146-153.
43. Kuoppamaki M, Seppala T, Syvalahti E, Hietala J. Chronic clozapine treatment decreases 5-hydroxytryptamine1C receptor density in the rat choroid plexus: comparison with haloperidol. J Pharmacol Exp Ther. 1993; 264(3): 1262-1267.
44. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 1999; 21(Suppl 2): 106S-115S http:// www.nature.com/npp/journal/v21/n1s/full/1395370a.html/.
45. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs. 2002; 16(1): 23-45.
46. Spurney CF, Baca SM, Murray AM, Jaskiw GE, Kleinman JE, Hyde TM. Differential effects of haloperidol and clozapine on ionotropic glutamate receptors in rats. Synapse. 1999; 34(4): 266-276.
47. Aghajanian GK, Marek GJ. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Brain Res Rev. 2000; 31(2-3): 302-312.
48. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol. 2001; 41: 237-260.
49. Tascedda F, Blom JM, Brunello N, et al. Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats. Biol Psychiatry. 2001; 50(2): 117-122.
50. Tascedda F, Lovati E, Blom JM, et al. Regulation of ionotropic glutamate receptors in the rat brain in response to the atypical antipsychotic Seroquel (quetiapine fumarate). Neuropsychopharmacology. 1999; 21(2): 211-217.
51. Watson DJ, King MV, Gyertyan I, Kiss B, Adham N, Fone KC. The dopamine D3-preferring D2/D3 dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia. Eur Neuropsychopharmacol. 2016; 26(2): 208-224.
52. Schmidt WJ, Bubser M. Anticataleptic effects of the N-methyl-daspartate antagonist MK-801 in rats. Pharmacol Biochem Behav. 1989; 32(3): 621-623.
53. Yoshida Y, Ono T, Kizu A, Fukushima R, Miyagishi T. Striatal N-methyl-d-aspartate receptors in haloperidol-induced catalepsy. Eur J Pharmacol. 1991; 203(2): 173-180.
54. Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol. 2002; 42: 165-179.
55. Gao XM, Sakai K, Roberts RC, Conley RR, Dean B, Tamminga CA. Ionotropic glutamate receptors and expression of N-methyl-daspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry. 2000; 157(7): 1141-1149 http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi. ajp.157.7.1141.
56. Ariano MA, Larson ER, Noblett KL, Sibley DR, Levine MS. Coexpression of striatal dopamine receptor subtypes and excitatory amino acid subunits. Synapse. 1997; 26(4): 400-414.